<DOC>
	<DOCNO>NCT01371721</DOCNO>
	<brief_summary>This 6-month , open-label , flexible-dose study evaluate desvenlafaxine succinate sustain release ( DVS SR ) treatment child adolescent outpatient major depressive disorder ( MDD ) .</brief_summary>
	<brief_title>A 6-Month Open-Label Extension Study B2061014 Study Evaluate Safety , Tolerability Efficacy DVS SR Treatment Children Adolescents With MDD</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Completed study B2061014 investigator 's opinion would benefit long term treatment DVS SR Willingness ability comply schedule visit , treatment plan procedures Subject require precaution suicide Subject generally healthy condition</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>MDD</keyword>
	<keyword>Depression</keyword>
</DOC>